
Arch Biopartners is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio spans both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect millions of patients worldwide. Arch’s lead drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI, a condition that affects more than 10 million people annually in the U.S. and Europe. AKI represents an ideal initial focus, as success in this area could…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPublicMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.